| About the author: |
I. V. Khubetova, A. I. Gozhenko |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Parkinson's disease remains the most common neurodegenerative disease affecting 1–2 ‰ of the population. The aim of the study was to identify prognostically significant factors that determine the course of Parkinson’s disease in the short term. The study was performed on the basis of the regional clinical hospital (Odesa) in 2017–2021. The data of the examination of 364 patients with verified Parkinson’s disease , including 198 men (54.4 %) and 166 women (45.6 %), were analyzed. The average age of the patients was 63.2±0.6 years. There was found that the most significant predictors for predicting the course of Parkinson’s disease are the severity of motor and cognitive disorders, the age of onset and the duration of the disease. |
| Tags |
Parkinson's disease,diagnosis,prognosis,clinical outcomes,clinical monitoring |
| Bibliography |
- Antomonov MYu. Matematicheskaya obrabotka i analiz mediko–biologicheskih dannyh. K. 2017. 578 p. [in Russian]
- Maiboroda RE, Sugakova OV. Statystychnyi analiz danykh za dopomohoyu paketa STATISTICA. K. 2012. 65 p. [in Ukrainian]
- Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020 Feb 11;323(6):548–560. doi: 10.1001/jama.2019.22360.
- Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020 Jan;27(1):27–42. doi: 10.1111/ene.14108.
- Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The Incidence of Parkinson's Disease: A Systematic Review and Meta–Analysis. Neuroepidemiology. 2016;46(4):292–300. doi: 10.1159/000445751.
- Lawton M, Baig F, Toulson G, Morovat A, Evetts SG, Ben–Shlomo Y et al. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort. Mov Disord. 2020 Feb;35(2):279–287. doi: 10.1002/mds.27888.
- Macleod AD, Dalen I, Tysnes OB, Larsen JP, Counsell CE. Development and validation of prognostic survival models in newly diagnosed Parkinson's disease. Mov Disord. 2018 Jan;33(1):108–116. doi: 10.1002/mds.27177.
- Parnetti L, Gaetani L, Eusebi P, Paciotti S, Hansson O, El–Agnaf O et al. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol. 2019 Jun;18(6):573–586. doi: 10.1016/S1474–4422(19)30024–9.
- Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S et al. Update on treatments for nonmotor symptoms of Parkinson's disease–an evidence–based medicine review. Mov Disord. 2019 Feb;34(2):180–198. doi: 10.1002/mds.27602.
- Tang Y, Wang J, Chen G, Ye W, Yan N, Feng Z. A simple–to–use web–based calculator for survival prediction in Parkinson's disease. Aging (Albany NY). 2021 Feb 1;13(4):5238–5249. doi: 10.18632/aging.202443.
- Tarianyk KA, Kaidashev IP, Shlykova OV, Izmailova OV. The analysis of the change in ghrelin level in patients with different forms of Parkinson’s disease. Svit medytsyny ta biolohiyi. 2020; 4 (74): 145–149.
- Tarianyk KA, Lytvynenko NV, Oliinychenko VK, Byslik TV, Pochernyaev KF. Adaptation of polymerase chain reaction–restriction fragment length polymorphism method for polymorphism (RS2583988) analysis in alpha–synuclein gene. Світ медицини та біології. 2020; 3 (73): 130–134.
- Velseboer DC, de Bie RM, Wieske L, Evans JR, Mason SL, Foltynie T et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology. 2016 Mar 15;86(11):986–93. doi: 10.1212/WNL.0000000000002437.
|
| Publication of the article |
«World of Medicine and Biology» №4(82), 2022 year, 187-191 pages, index UDK 616.858–008.6–079.4 |
| DOI |
10.26724/2079-8334-2022-4-82-187-191 |
